Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study
Crossref DOI link: https://doi.org/10.1007/s11060-016-2155-4
Published Online: 2016-06-10
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Jakacki, Regina I.
Foley, Margaret A.
Horan, Julie
Wang, Jiuzhou
Kieran, Mark W.
Bowers, Daniel C.
Bouffet, Eric
Zacharoulis, Stergios
Gill, Stan C.
Funding for this research was provided by:
Astellas Pharma Global Development
License valid from 2016-06-10